OncoMatch/Clinical Trials/NCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Is NCT06930755 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including NMS-03305293 and Topotecan for ovarian cancer.
Treatment: NMS-03305293 · Topotecan — This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: anticancer therapy
Patient must have progressed radiographically on or after their most recent line of anticancer therapy
Cannot have received: PARP inhibitor
Exception: outside of approved indication and schedules
Prior therapy with PARP inhibitor, outside of approved indication and schedules
Cannot have received: topoisomerase inhibitor
Exception: Sponsor has the option to allow prior ADC, if not last line of treatment, prior to enrollment
Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs)
Cannot have received: wide-field radiotherapy affecting at least 20 percent of the bone marrow
Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OSF Saint Francis Medical Center · Peoria, Illinois
- Washington University School of Medicine in St. Louis · St Louis, Missouri
- Penn Medicine - Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
- Tennessee Oncology · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06930755 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, topoisomerase inhibitor, wide-field radiotherapy affecting at least 20 percent of the bone marrow disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages